Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.58 |
| ▸ | PDE4A | P27815 | 12/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.58 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435624 | 0.90 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2881703 | 0.90 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6435630 | 0.90 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL5553386 | 0.89 | PDE4D (0.78) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL7174829 | 0.89 | PDE4D (0.66) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2888216 | 0.89 | PDE4D (0.66) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2886875 | 0.87 | PDE4D (0.63) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL5875874 | 0.87 | PDE4D (0.63) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2887808 | 0.86 | PDE7B (0.73) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2889809 | 0.86 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CPDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531540-B2 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2007-06-07 | — | — | US | disclosed |
| US-7179810-B2 | Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders | ALTANA PHARMA AG (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2005-10-20 | — | — | US | disclosed |
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | disclosed |
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | PDE4D 19/4885PDE4B 11/4885PDE4A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.